Targeting non-coding RNAs to overcome cancer therapy resistance
Abstract
It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy—especially the development of delivery systems.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 13, 2022
- Source ID
- 10.1038/s41392-022-00975-3
Entities
People
- Baoqing Chen
- Chen Yang
- David Horst
- George A. Calin
- Mihnea P. Dragomir
- Qiaoqiao Li
Organizations
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Institute of General Medical Sciences
- National Natural Science Foundation of China
- United States Department of Defense
- United States Department of Health and Human Services